First Tracks Biotherapeutics Closes Private Placement of 6,106,870 Shares

First Tracks Biotherap is Maintained at Outperform by Leerink Partners

First Tracks Biotherapeutics Inc (TRAX) Receives a Rating Update from a Top Analyst

First Tracks Biotherapeutics Inc : Leerink Partners Raises Target Price to $90 from $70

US Stocks on the MOVE-Caterpillar, Kimberly-Clark, Bending Spoons

First Tracks Biotherapeutics Shares Rise 1% After $200 Million Equity Raise

First Tracks Biotherapeutics up After $200 Mln Equity Raise

First Tracks Biotherapeutics announces $200M private placement

First Tracks Biotherapeutics - Proceeds to be Used for Corporate Purposes and Clinical Development of Anb033

First Tracks Biotherapeutics - to Sell 6,106,870 Shares at $32.75 Per Share in Private Placement

First Tracks Biotherapeutics Announces $200 Million Private Placement

Health Rounds: New Drug Treats Gluten-Caused Intestinal Damage in Celiac Patients

First Tracks Biotherap Price Target Raised to $70.00/Share from $65.00 by Evercore ISI Group

Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)

US Research Roundup-Essex Property Trust, Qualys, Vulcan Materials

US Stocks on the MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences

First Tracks Biotherapeutics Shares Rise 13.3% Premarket After Positive Results from Celiac Disease Drug Trial

First Tracks Reports Positive Trial Results for Celiac-Disease Treatment

First Tracks Says Anb033 Meets Key Histologic, Symptom Endpoints in Phase 1b Celiac Gluten-Challenge Study